High-intensity focused ultrasound in the management of prostate cancer

Expert Review of Medical Devices

Volumn 7, Issue 2, 2010, Pages 209-217

  Chaussy, Christian ^a   Thüroff, Stefan ^a  

^a Klinikum Harlaching   (Germany)

Author keywords

Focal treatment; Minimal invasive therapy; Prostate cancer; RHIFU; Robotic high intensity focused ultrasound; Uro oncology

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PROSTATE SPECIFIC ANTIGEN;

CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD4 CD8 RATIO; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; EXTRACORPOREAL LITHOTRIPSY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; ROBOTICS; SALVAGE THERAPY; STRESS INCONTINENCE; SURVIVAL RATE; SURVIVAL TIME; TISSUE PRESERVATION; TRANSURETHRAL RESECTION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR VOLUME;

EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 77949385824     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.66     Document Type: Review

References (44)

1. Chaussy C, Brendel W, Schmiedt E. Extracorporeally induced destruction of kidney stones by shockwaves. Lancet 2(8207), 1265-1268 (1980).
2. Lynn JG, Putman TJ. Histological and cerebral lesions produced by focused ultrasound. Am. J. Pathol. 20, 637-649 (1944).
3. Chaussy C, Thueroff S, Rebillard X, Gelet A. Technology insight: high-intensity focused ultrasound for urologic cancers. Nat. Clin. Pract. Urol. 2(4), 191-198 (2005).
4. Gelet A, Chapelon JY, Poissonnier L et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63(4), 625-629 (2004).
5. Chaussy C, Thueroff S. Complete remission in metastatic prostate cancer after combined local and systemic therapy. Urology 68, 197-198 (2006).
6. Ficarra V, Antoniolli SZ, Novara G et al. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int. 98, 1193-1198 (2006).
7. ASTRO. Consensus Statement. Guidelines for PDSA following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 37, 1035-1041 (1997).
8. Gelet A, Chapelon JY, Bouvier R et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur. Urol. 29, 174-183 (1996).
9. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J. Urol. 161, 156-162 (1999).
10. Gelet A, Chapelon JY, Bouvier R et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J. Endourol. 14, 519-528 (2000).
11. Richaud P, Moreau JL, Beuzeboc P et al. [Follow-up of prostate cancer. Guidelines of the French Urological Association Oncology Committee.] Prog. Urol. 15, 586-592 (2005).
12. Chaussy C, Thüroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J. Endourol. 15, 437-440 (2001).
13. Gelet A, Chapelon JY, Bouvier R et al. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors infuencing the outcome. Eur. Urol. 40, 124-129 (2001).
14. Poissonnier L, Gelet A, Chapelon JY et al. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA or + 10ng/ml.)] Prog. Urol. 13;1;60-72: 2003.
15. Thüroff S, Chaussy C, Vallancien G et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J. Endourol. 17, 673-677 (2003).
16. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 63(2), 297-300 (2004).
17. Poissonnier L, Chapelon JY, Rouvière O et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur. Urol. 51, 381-387 (2007).
18. Blana A, Murat FJ, Walter B et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur. Urol. 53(6), 1194-1201 (2008).
19. Blana A, Rogenhofer S, Ganzer R et al. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 72(6), 1329-1333 (2008).
20. Blana A, Brown CW, Chaussy C et al. Primary prostate HIFU without pretreatment hormone therapy: biochemical survival of 763 patients tracked with the @-Registry. Eur. Urol. 8(4), 333 (2009) (Abstract 850).
21. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specifc mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specifc antigen era. J. Clin. Oncol. 21(11), 2163-2172 (2003).
22. Chaussy C, Thüroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr. Urol. Rep. 4, 248-252 (2003).
23. Vallancien G, Prapotnich D, Cathelineau X et al. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J. Urol. 171(6 Pt 1), 2265-2267 (2004).
24. Hayashi M, Shinmei S, Asano K. Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy. Int. J. Urol. 14, 1048-1050 (2007).
25. Murat FJ, Poissonnier L, Rabilloud M et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol. 55(3), 640-647 (2009).
26. Thüroff S, Chaussy C, Gelet A. Focused ultrasound (HIFU) in the treatment of prostate cancer. energy/efficacy correlation. WCE Congress, 2001. J. Endourol. 15(Suppl. 1), 32 (2001) (Abstract A3-P10).
27. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specifc antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int. 98, 537-539 (2006).
28. Ganzer R, Rogenhofer S, Walter B et al. PSA nadir is a signifcant predictor of treatment failure after high-intensity focused ultrasound (HIFU) treatment of localised prostate cancer. Eur. Urol. 53, 547-553 (2008).
29. Onik G, Barzell W. Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol. Oncol. 26(5), 506-510 (2008).
30. Rouvière O, Souchon R, Salomir R et al. Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur. J. Radiol. 63, 317-327 (2007).
31. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur. Urol. 50, 1163-1174 (2006).
32. Kim JK, Hong SS, Choi YJ et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J. Magn. Reson. Imaging 22(5), 639-646 (2005).
33. Haider MA, van der Kwast TH, Tanguay J et al. Combined T2-weighted and diffusion weighted MRI for localization of prostate cancer. Am. J. Roentgenol. 189(2), 323-328 (2007).
34. Rouvière O, Lyonnet D, Raudrant A et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur. Urol. 40, 265-274 (2001).
35. Kirkham AP, Emberton M, Hoh IM et al. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 246, 833-844 (2008).
36. Wu T, Felmlee JP, Greenleaf JF et al. Assessment of thermal tissue ablation with MR elastography. Magn. Reson. Med. 45, 80-87 (2001).
37. Vaezy S, Shi X, Martin RW et al. Real-time visualization of high intensity focused ultrasound treatment using ultrasound imaging. Ultrasound Med. Biol. 27, 33-42 (2001).
38. Sedelaar JP, Aarnink RG, van Leenders GJ et al. The application of three-dimensional contrast-enhanced ultrasound to measure volume of affected tissue after HIFU treatment for localized prostate cancer. Eur. Urol. 37, 559-568 (2000).
39. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn. J. Clin. Oncol. 38(3), 192-199 (2008).
40. Wu F, Wang ZB, Lu P et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med. Biol. 30(9), 1217-1222 (2004).
41. Wu F, Wang ZB, Cao YD et al. Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation. Ann. Surg. Oncol. 14(3), 1237-1242 (2007).
42. Hu Z, Yang XY, Liu Y et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J. Transl. Med. 5, 34 (2007).
43. Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J, Wu F. Increased infltration of activated tumor-infltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery 145(3), 286-293 (2009).
44. Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 9, 439-443 (2006).